Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupSarcomasTransplantationDiseaseEwing SarcomaStem Cell Transplantation, AutologousSubgroupICD10C40.-C41.-Z94.80MeSHSarcoma, EwingSequenceChemotherapyChemo-substanceMelphalanTreosulfanChemo-substanceMelphalanTreosulfanChemo-substanceMelphalanTreosulfanChemo-substanceMelphalanTreosulfanNo. Substances2 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityhigh doseTherapy indicationFirst lineTherapy phaseautologous stem cell transplantationTherapy intentioncurativeRisks only studiesPublicationAuthorDirksen UDiseaseprimär disseminiertes Ewing Sarkom, Alter unter 50OriginFunctional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (EWING 2008)Protocols in Revision 1 protocol foundProtocols under revision.Melphalan 140 / Treosulfan 12, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID1396 V2.1)
